Does Rallies show 13F holders for ACRS?

Yes. Rallies tracks hedge fund and 13F ownership data for ACRS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACRS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACRS. It does not provide personalized investment advice.

ACRS (Aclaris Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Aclaris Therapeutics, Inc. (ACRS) is a publicly traded Healthcare sector company. As of May 21, 2026, ACRS trades at $4.37 with a market cap of $614.52M and a P/E ratio of -7.97. ACRS moved +1.80% today. Year to date, ACRS is +70.94%; over the trailing twelve months it is +235.56%. Its 52-week range spans $1.05 to $5.17. Analyst consensus is strong buy with an average price target of $10.38. Rallies surfaces ACRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACRS stock?

Hedge funds tracked by Rallies that own ACRS include Panagora Asset and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aclaris Therapeutics, Inc..

ACRS Key Metrics

Key financial metrics for ACRS
Metric	Value
Price	$4.37
Market Cap	$614.52M
P/E Ratio	-7.97
EPS	$-0.56
Dividend Yield	0.00%
52-Week High	$5.17
52-Week Low	$1.05
Volume	310
Avg Volume	0
Revenue (TTM)	$8.37M
Net Income	$-69.66M
Gross Margin	76.34%

Top Hedge Funds Holding ACRS

Panagora Asset holds 502.29K shares of ACRS, changed +636.60% as of Mar 31, 2026.
Centerbook Partners holds 66.60K shares of ACRS, changed +0.00% as of Mar 31, 2026.

Latest ACRS News

Aclaris Raises $59.8M, Holds $190.8M Cash; ATI-052 Shows 45-Day Half-Life — May 7, 2026
Aclaris to Release Phase 1a SAD/MAD ATI-052 Results and ATI-2138 Indication Choice — Apr 27, 2026
Aclaris’s ATI-2138 Yields 77% EASI Reduction and 65% DLQI Gain — Mar 27, 2026
Aclaris Completes Enrollment of 109 Patients in Phase 2 Atopic Dermatitis Trial and Sets Q4 2026 Readout — Mar 18, 2026
Aclaris Outlines Q2 AD, Q3 Asthma Readouts After Q4 Earnings Preview — Feb 26, 2026

Recent ACRS Insider Trades

Leonard Braden Michael sold 300.00K (~$1.36M) on Apr 23, 2026.
Mehra Anand bought 666.67K (~$1.50M) on Nov 19, 2024.

ACRS Analyst Consensus

8 analysts cover ACRS: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.38.

Common questions about ACRS

Who owns ACRS stock?: Hedge funds tracked by Rallies that own ACRS include Panagora Asset and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aclaris Therapeutics, Inc..
Does Rallies show 13F holders for ACRS?: Yes. Rallies tracks hedge fund and 13F ownership data for ACRS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACRS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACRS. It does not provide personalized investment advice.